Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590979 · ClinicalTrials.gov registry record · NA
Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation
A NA study, sponsored by Northwell Health.
- Terminated
- Registry status
- NA
- Development phase
- 54
- Enrollment target
NCT01590979 is a NA study that was terminated before completion, run by Northwell Health. The registered enrollment target is 54 participants.
The verdict
NCT01590979, a NA study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the prophylactic effects of Ranolazine on new onset atrial fibrillation in post-operative coronary artery bypass graft and valve surgery patient population at Staten Island University hospital.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01590979
The ClinicalTrials.gov registry entry for NCT01590979 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01590979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01590979 about?
NCT01590979 is a clinical study titled "Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation". The aim of this study is to evaluate the prophylactic effects of Ranolazine on new onset atrial fibrillation in post-operative coronary artery bypass graft and valve surgery patient population at Staten Island University hospital.
What is the current status of trial NCT01590979?
This trial is currently terminated. It is a NA study. The enrollment target is 54 participants. The study started on 2012-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01590979?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01590979?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.